Compare Incyte Corporation (INCY) vs Vanguard Ultra Short Bond ETF (VUSB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Incyte Corporation vs Vanguard Ultra Short Bond ETF — how do they compare? Incyte Corporation trades at $121.06 (market cap $24.54B), while Vanguard Ultra Short Bond ETF trades at $49.69. The key difference: Incyte Corporation is trading nearer its 52-week high, Vanguard Ultra Short Bond ETF nearer its low. Which is the better fit depends on your goals.
| INCY | VUSB | |
|---|---|---|
Market Cap | $24.54B | — |
Sector | Health | Leveraged / Inverse |
52-Week High | $129.93 | $50.03 |
52-Week Low | $81.61 | $49.60 |
Enterprise Value | $20.04B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Incyte Corporation (INCY) trades at $120.79, down 0.63% today, but maintains a bullish technical trend with strong fundamental performance. The stock is near its 52-week high, supported by robust earnings beats in Q1 and Q2 2026, with revenue growth accelerating to $5.14 billion in 2025. Recent news highlights regulatory approvals for Opzelura in the EU and a raised 2026 revenue outlook following a favorable CMS settlement.
The outlook remains positive given strong analyst consensus (52% buy ratings) and a $122.82 price target, though risks include reliance on key products and competitive pressures. Earnings momentum and institutional accumulation suggest further upside, but investors should monitor execution on growth initiatives.
VUSB trades at $49.685, showing minimal daily movement with a 0.05% gain. Technical indicators signal a bearish trend, with moving averages and key momentum oscillators like the ADX indicating selling pressure. Recent news highlights the ETF's focus on short-term bonds amid expectations of Federal Reserve rate hikes, positioning it as a potential hedge against interest rate risk.
The outlook for VUSB is cautious due to bearish technical signals and sensitivity to interest rate changes. Opportunities lie in its short-term bond strategy if rates rise, but risks include market volatility and economic shifts. Investors should weigh the ETF's defensive role against prevailing macroeconomic uncertainties.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →About Vanguard Ultra Short Bond ETF
VUSB is an actively managed ETF from Vanguard that invests in a diversified portfolio of high-quality, investment-grade fixed income securities with maturities typically under two years. It is designed to offer higher yield potential than traditional money market funds while maintaining limited price volatility, making it a strategic tool for managing short-term reserves with a 6-to-18-month horizon.
Read more on VUSB →
